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2

DRUG DELIVERY SYSTEM INVOLVING
INTERACTION BETWEEN PROTEIN OR
POLYPEPTIDE AND HYDROPHOBIC
BIODEGRADABLE POLYMER

[Yolles, S., “Time-Release Depot for Anticancer Drugs:
Release of Drugs Covalently Bonded to Polymers”, J.
Parent. Drug Assoc., 32, 188(1978)]. The release of a
number of anti-tumor agents has been evaluated in implant
able systems as reported in [Yolles, S., “Time Release Depot
for Anticancer Drugs: Release of Drugs Covalently Bonded
to Polymers”, J. Parent. Drug Assoc., 32, 188 (1978)], and
the antibiotic Mitomycin C has been encapsulated in micro

This application is a continuation of application Ser. No.
07/865,657, ?led Apr. 7, 1992, noW abandoned; Which is a
continuation of application Ser. No. 07/716,763, ?led Jun.
19, 1991 (noW abandoned); Which is a continuation of

application Ser. No. 07/554,427, ?led Jul. 19, 1990 (noW

spherical carriers of gelatin and administered intravenously
10

abandoned).

Intern. J. Pharm., 81, 131 (1981)] and the effect of siZe on
in vivo distribution and the potential for antibiotic targeting
Was discussed. The siZe distribution of the microspheres

BACKGROUND OF THE INVENTION

(1) Field of the Invention
The present invention relates generally to the ?eld of
biodegradable polymers for the controlled release of bio
logically active agents therefrom. More particularly, the
present invention relates to a process for preparing hydro
phobic biodegradable polymers of controlled siZe in Which
there is a physical interaction With the protein or polypeptide
incorporated therein. Such an interaction promotes incorpo
ration of the protein or polypeptide into the polymer matrix
and alloWs for protection and controlled release of the

protein or polypeptide from the polymer.
(2) Background of the Prior Art

15

(i.e., 5 to 30 pm) reported in the last mentioned publication
Was very broad, especially for intravenous administration.
Recently the in-vitro release of local anesthetics from poly

lactic acid spheres prepared by a solvent evaporation process

has, likeWise, been reported [Wakiyama, N., Kaxuhiko, J.,
20

Nakano, M., “In?uence of Physicochemical Properties of
Polylactic Acid on the Characteristics and In Vitro Release

Patterns of Polylactic Acid Microspheres Containing Local
Anesthetics”, Chem. Pharm. BulL, 30, 2621 (1982)]. The
patterns of release from these polylactic acid spheres Were
25

characteriZed by the various degrees of degradation of the
polymer as Well as solubilities of loaded drugs, although no
attempt Was apparently made to evaluate this parameter.

AWide variety of microencapsulation drug delivery sys

Additionally, it is apparent that the solubility of the drug

tems have been developed heretofore for the rate controlled

release of therapeutic agents or other agents. For instance,
considerable research has been devoted to incorporating

[Yoshioka, T., Hashida, M., Muranishi, S., and SeZaki, H.,
“Speci?c Delivery of Mitomycin C. to Liver, Spleen and
Lung: Nano- and Microspherical Carriers of Gelatin”,

played an important role in the rate and extent of release.
30

Scanning electron photomicrographs also revealed varying

therapeutic agents into polyesters such as poly-e

degrees of erosion and deformation of the spheres after

caprolactone), poly(e-caprolactone-Co-DL-lactic acid), poly
(DL-lactic acid), poly(DL-lactic acid-Co-glycolic acid) and

release.
It Will be seen from the foregoing that While the controlled

poly(e-caprolactone-Co-glycolic acid) in Which release Was
diffusion controlled. See, for example, Pitt, C. G., GratZl, M.

release delivery of pharmaceuticals or other agents from
35

Were fabricated as ?lms and capsules and the results suggest
that the devices can be prepared to erode after release of the

considerations relative to pore siZe and/or cell siZe Within
the carrier matrix as Well as the overall dimensions of the
40

drug is essentially complete. Degradation of the polyesters
has been reported to proceed by random hydrolytic cleavage

microspheres to be administered along With the rate of
release and the relative absorption rate from a bioavailability
standpoint are distinctly different from the evaluation
parameters involved in the utiliZation of these microsphere

delivery systems for parenteral, i.e., intravenous,

of ester linkages by an autocatalytic process With the rate of

chain cleavage being in?uenced by chemical and morpho
logical factors.

heretofore described polymeric systems has been principally
limited to oral, topical or implantable systems in Which the

M., Jeffcoat, A. R., ZWeidinger, R., Schindler, A., “Sustained
Drug Delivery Systems. II. Factors Affecting Release Rates
from Poly(e-caprolactone) and Related Biodegradable
Polyesters”,J. Pharm. Sci., 68, 1534 (1979). These systems

intraarterial, intramuscular, subcutaneous, intraocular or
45

inhalation administration routes to Which the present inven

tion is particularly applicable.
For instance, US. Pat. No. 4,818,542 describes a con

Sustained release systems of antimalarial agents and
sulfadiaZine in glycolic-lactic acid copolymers have also

been reported. Wise, D. L., Gesser, J. D., McCormick, G. J.,

trolled release drug delivery system comprised of a spherical
microprocess polymeric netWork of interconnecting chan

“Sustained Release of a Dual Anti-malarial System”, J.

nels.

Pharm. PharmacoL, 31, 201 (1979). Wise, D. L.,

Further, the use of proteins and peptides as therapeutic
agents has been recogniZed and their position Within the
pharmaceutical armamentarium is groWing due to their
increasing availability. This availability is primarily due to
recent advances in genetic engineering and biotechnology.
Unfortunately, the use of proteinaceous drugs by conven
tional routes of administration is generally hampered by a

McCormick, G. J ., Willett, G. R, Anderson, L. C., HoWes, J.

F., J. Pharm. PharmacoL, 30, 686 (1978). Methods reported
by the foregoing investigators involved dissolving the
agents in a suitable solvent and either spray drying or casting
?lms according to usual methods and evaporating the sol
vent. Various narcotic antagonists and steroids have been
incorporated in ?lms and implanted in rats (e.g., see

Woodland, J. H. R., Yolles, S., Blake, D. A., Helrich, M.,
Meyer, F. J., “Long-Acting Delivery Systems for Narcotic
Antagonists: I”, J. Med. Chem., 16, 897 (1973), JackanicZ,
T. M., Nash, H. A., Wise, D. L., Gregory, J. B., “Polylactic

55

variety of delivery problems. Nonparenteral routes of
administration, i.e., oral and percutaneous, are inef?cient
60

Acid as a Biodegradable Carrier for Contraceptive

Steroids”, Contraception, 8, 227 (1973). Anderson, L. C.,
Wise, D. L., HoWes J. F., “An Injectable Sustained Release

Fertility Control System”, Contraception, 13, 375 (1976)
and incorporated into particles injected subcutaneously

65

primarily due to poor absorption of proteinaceous drugs into
the bloodstream and degradation of such drugs in the
gastrointestinal tract. Rapid proteolytic inactivation of the
proteinaceous drug also occurs When the drug is adminis
tered parenterally thus decreasing its bioavailability. In
addition, When administered by the parenteral route, the
host’s immune system is activated thereby potentially set
ting off a series of undesirable immune reactions.

US 6,306,406 B1
4

3
In vieW of the foregoing, considerable effort has been

carboxyloxy, a methylene carboxamido or a methylene
sulfonamido group attached to a polymethylene chain Which
itself has a functional group suitable for coupling With a

devoted to developing alternative systems for parenteral
delivery of peptides and proteins to obviate the problems

polymer; R3 represents a biologically inert polymer; and R4
represents a ?uorogenic moiety.

associated With prior art administration techniques. For
instance, implantable devices have been cast or molded from

poly-(hydroxy-ethyl)methacrylate, polyvinyl alcohol,
ethylene-vinylacetate copolymer (EVA) and silicone elas

GB 2 207 050 discloses a composition comprising an
aqueous solution of a drug and a glucose polymer mixture

tomer. Macromolecular drugs have been embedded in those

Which includes at least 50% by Weight of glucose polymers

devices. A typical method of preparation involves suspend
ing a poWder of a macromolecular drug such as a solid

10

of DR greater than 12. The composition is introduced into
the peritoneal cavity. The glucose polymers act as osmotic

agents during peritoneal dialysis.

protein or peptide in a solution containing the polymer. The
entire composition is then case or molded into the desired

EP 0 354 714 discloses a pharmaceutical composition for

siZe and shape either by evaporating the solvent or by

affecting tissue redistribution of bioactive peptides and
proteins Which are normally bound to glycoaminoglycans,
and for mimicking the action of glycoaminoglycans in
biological interactions. The composition comprises a phar

vulcaniZation. A sustained release of macromolecules from
these devices has been demonstrated. The simplicity of the

15

foregoing prior art method is its primary advantage.
To avoid the foregoing dif?culties, U.S. Pat. No. 4,741,
872 discloses a method for preparing biodegradable micro
spheres having a three-dimensional netWork in Which bio
logically active macromolecular agents are physically

maceutically acceptable polymeric compound having mono

entrapped therein.

meric units and a molecular Weight betWeen 1,000 and
20,000 Daltons, Wherein each monomeric unit contains
betWeen three and about 10 aromatic rings.
EP 0 187 547 relates to polymeric drugs comprising an

A number of other types of protein/polymer systems are
knoWn in the art. For instance, U.S. Pat. Nos. 3,843,446,

inert synthetic polymeric carrier covalently attached to loW
molecular Weight bioactive molecules. Drug delivery is

3,977,941 and 4,601,981 discloses the preparation of enZy

matically active protein-enZyme complex membrane by

20

someWhat targeted because uptake is restricted to cells
25

treating another protein membrane With an aqueous solution

In spite of the numerous teachings of the prior art, the
prior art drug delivery systems still have some signi?cant

of an enZyme. The membranes are used to effect enZymatic

reactions.
US. Pat. No. 3,972,776 discloses the preparation of

enZymatically active protein-Whole microbial cell complex
membranes suitable for effecting enZymatic reactions by
forming a dispersion containing synthetic or natural protein

disadvantages and commercialiZation has been difficult to
30

SUMMARY OF THE INVENTION

It is, therefore, the object of this invention to provide one
35

proteins into a hydrophobic biodegradable polymer to pro

US. Pat. No. 4,758,342 relates to a hyper?ltration mem

controlled release of the polypeptide or protein from the
40

active agent comprised of lignin sulfonic acids, and

polymer in vivo.
It is another object of the present invention to provide for
a drug delivery system itself Which alloWs for controlled
release of the polypeptide or protein from the polymer in

optionally, an alkylaryl sulfonic free acid With at least ten

carbon atoms and eight polypeptides having a molecular
Weight of about 2,500 to about 15,000.
US. Pat. Nos. 4,585,787 and 4,591,501 disclose a ?exible
continuous ?lm Which is comprised of a physical admixture
of a polypeptide, a plasticiZer and a ?lm-forming ?exible

or more processes for the incorporation of polypeptides and
vide a stable formulation and to achieve protection and

brane containing a supporting layer and a separation layer.
US. Pat. Nos. 4,494,944 and 4,557,855 disclose a surface

achieve especially With respect to sufficient drug loading,

reproducibility of product speci?cations and scale-up.

macromolecules and Whole microbial cells, casting a mem

brane from the dispersion and drying the membrane. The
membranes may also be formed by electro-codeposition
from a dispersion containing the macromolecular and cells.

capable of a substrate selective mechanism knoWn as

pinocytosis.

vivo, Wherein said incorporation, protection and controlled
release are due to the physical interaction betWeen the
45

polypeptide or protein and the hydrophobic biodegradable

polymer.
A still further object of the present invention is to provide

polymer, When the ?lm is moistened, the polypeptide exudes

a microspherical drug delivery system Which alloWs target

therefrom.

ing of drugs or other agents to speci?c host tissues or cells

via injection or inhalation providing high localiZed

US. Pat. No. 4,873,033 relates to a hyper?ltration mem

brane containing a supporting layer and a separation layer.

concentrations, sustained activity, systemic administration
and treatment, thereby minimiZing undesirable systemic

The separation layer consists of a crosslinked monomolecu
lar ?lm of molecules, the molecules of the separation layer
in the uncrosslinked state being surfactants or surfactant-like

effects of toxic drugs administered in the native form.
These and similar objects, advantages and features are

lipoids containing at least one hydrophobic chain and at least
one hydrophilic group. The surfactant-like lipoid molecules

accomplished according to the methods and compositions of
the folloWing description of the present invention.

are spread out under a certain spreading pressure or occupy

BRIEF DESCRIPTION OF THE DRAWINGS

an average space over the surface of an aqueous solution or

at the interface betWeen an aqueous solution and a liquid

immersible thereWith.
US. Pat. No. 4,897,444 relates to an immobiliZed ?uo
rogenic substrate. The substrate has the structure

60

FIG. 1 is a description of the precipitation method of

preparing the drug delivery system of the present invention.
FIG. 2 is a description of the microsphere method of

preparing the drug delivery system of the present invention.
FIG. 3 is a graph depicting the interaction of salmon
65

Wherein R1 represents an enZyme-speci?c oligopeptide, R2
represents a spacer group Which is a methylene

calcitonin (sCT) With polyglycolic acid, polylactic acid and
copolymers of glycolide and L-lactide at varying molar
concentrations of polymer.

US 6,306,406 B1
6

5

Polyglycolic/Poly(lactic acid) Homo- and Copolymers: 1”,
Polymer, 20, 1459 (1979).

FIG. 4 is a graph of the size distribution of salmon

calcitonin and polyglycolic acid microspheres.
polyglycolic acid MW=100,000 and salmon calcitonin

Any protein or polypeptide is suitable in the practice of
the present invention. Biologically active proteins or

microspheres prepared by freeZe drying. The targeted drug

polypeptides for use in the present invention are proteins or

FIG. 5 is a graph of the release of salmon calcitonin from

polypeptides of relatively small molecular Weights. Exem
plary preferred biologically active polypeptides for use
herein are calcitonin, insulin, angiotensin, vasopressin,

load Was 10%.

FIG. 6 is a graph of the release of salmon calcitonin from
a polyglycolic acid-salmon calcitonin precipitate. The tar
geted drug load Was 10%.
FIG. 7 is a graph of the serum calcium concentration over

10

desmopressin, LH-RH (luteiniZing hormone-releasing
hormone), somatostatin, glucagon, somatomedin, oxytocin,
gastrin, secretin, h-ANP (human atrial natriuretic

time of a salmon calcitonin/microsphere drug delivery sys

polypeptide), ACTH (adrenocorticotropic hormone), MSH

tem.

(melanocyte stimulating hormone), beta-endorphin,
DESCRIPTION OF THE PREFERRED
EMBODIMENTS OF THE INVENTION

15

A variety of hydrophobic biodegradable polymers are
suitable in the drug delivery system of the present invention.
sters and polyanhydrides.

various polypeptides for use herein include not only the
20

The polymer may comprise copolymeric and homopoly
meric polyesters containing hydrolyZable inter linkages
Which are, therefor, biodegradable. Typically preferred of
such polyesters are polyglycolic (PGA) and polylactic
(PLA) acids, and copolymers of glycolide and L-lactide
(PGL). The aforementioned polyesters are particularly

naturally occurring polypeptides themselves but also phar
macologically active derivatives and analogs thereof. Thus,
for example, calcitonin intended for use in the present

invention includes not only naturally occurring products
25

suited for the methods and compositions of the present
invention by reason of their characteristically loW human

toxicity and virtually complete biodegradability. of course, it

gene related peptide), endothelin, TRH (thyroid releasing
hormone), groWth hormones like erythropoietin, lymphok
ines like macrophage stimulating factor, and the like. The

Such polymers are Well-knoWn to those of ordinary skill in

this art. Suitable polymers include polyesters, polyorthoe

muramyl dipeptide, enkephalin, neurotensin, bombesin, VIP,
CCK-8, PTH (parathyroid hormone), CGRP (calcitonin

30

such as salmon calcitonin, human calcitonin, porcine
calcitonin, eel calcitonin and chicken calcitonin, but also
analogs such as [Asu1’7]-eel calcitonin elcatonin, a product
of Toyo JoZo Company, Ltd., as Well. Similarly, LH-RH for
use herein includes not only the naturally occurring product
but also the pharmaceutically active derivatives and analogs
thereof such as described in various patents and publications

Will be understood that the particular polyester or other

referenced hereinabove, e.g., MatsuZaWa et al US. Pat. No.

polymer, oligomer, copolymer, and the like, utiliZed in the

3,917,825. Especially preferred polypeptides for use in the
present invention include calcitonin, insulin, ACTH,
LH-RH, PTH, CGRP, somatostatin and somatomedin. Cal

present invention is not critical and a variety of hydrophobic
biodegradable polymers may be utiliZed as a consequence of

the novel processing methods of the invention Which yield
the desired drug delivery system, irrespective of the source
of polymer utiliZed.
Accordingly, other biodegradable or bioerodable poly
mers or copolymers evidencing the necessary loW degree of
toxicity suitable for use in the present invention include, for

35

citonin is the most preferred.

Biodegradable synthetic polypeptides include poly-(N

hydroxyalkyl)-L-asparagine, poly-(N-hydroxy-alkyl)-L
glutamine, copolymers of N-hydroxyalkyl-L-asparagine and
40

N-hydroxyalkyl-L-glutamine With other amino acids.
De?nitions or further description of any of the foregoing

example, gelatin, agar, starch, arabinogalactan, albumin,

terms and phrases are Well knoWn in the art and may be

collagen, natural and synthetic materials or polymers, such

found by referring to any standard biochemistry reference
text such as “Biochemistry” by Albert L. Lehninger, Worth
Publishers, Inc. and “Biochemistry” by Lubert Stryer, W. H.
Freeman and Company, both of Which are hereby incorpo
rated by reference.
The amount of the biologically active peptide in the drug
delivery system of the present invention Will vary, depend
ing upon the particular polypeptide employed, but Will be an

as poly(e-caprolactone), poly(e-caprolactone-Co-lactic

acid), poly(e-caprolactone-Co-glycolic acid), poly([3
hydroxy butyric acid), polyethylene oxide, polyethylene,
poly(alkyl-2-cyanoacrylate), (e.g., methyl, ethyl, butyl, and
the like), hydrogels (e.g., poly(hydroxyethyl methacrylate
poly-hydroxyethyl methacrylate), polyamides (e.g.,
polyacrylamide), poly(amino acids)(i.e., L-leucine,
L-aspartic acid, [3-methyl-L-aspartate, [3-benZyl-L-aspartate,

45

amount sufficient to elicit the desired pharmacological

glutamic acid and the like), poly(2-hydroxyethyl-DL

aspartamide), poly(ester urea), poly(L-phenylalanine/
ethylene glycol/1,6-diisocyanatohexane), poly(methyl
methacrylate), 3,9-bis methylene-2,4,8,10-tetraoxaspirol
[5,5] undecane, 1,6-hexadiol polyorthoester, poly(bis-p
carboxyphenoxypropane anhydride), ethylene-vinylacetate

effect. Thus, for example, When the selected polypeptide is
calcitonin, such Will be present in an amount sufficient to
treat a condition such as Paget’s disease or hypercalcemia or

osteoporosis. A typical preparation may contain, for
55

example, from about 0.01 to about 0.04 I.U./mg for porcine
calcitonin. In the case of insulin, an amount sufficient to

copolymer (EVA), polyvinyl alcohol (PVA) and silicone

control blood sugar levels and thus to treat diabetes Will

elastomer.

typically be employed; in the case of LH-RH or analog
thereof, an amount sufficient to treat diabetes Will typically
be employed; in the case of LH-RH or analog thereof, an

The foregoing exemplary natural and synthetic polymers
suitable for use in the present invention are, of course, either

60

readily available commercially or are obtainable by conden
sation polymeriZation reactions from the suitable monomers
or, comonomers or oligomers. For instance, homopolymers
and copolymers of glycolic and lactic acids can be prepared

by direct poly-condensation or by reacting glycolide and
lactide monomers as disclosed by Gilding, D. K., Reed, A.

M., “Biodegradable Polymers for Use in Surgery—

amount sufficient to treat various disorders of the female
reproductive system, an amount sufficient to have a contra
ceptive effect, or an amount sufficient to elicit any other
65

knoWn biological response to LH-RH Will be used, in the
case of PTH, CGRP, somatomedin or analog thereof, an
amount sufficient to treat various disorders of bone metabo
lism Will be used; and so on for the other biologically active

US 6,306,406 B1
8

7
peptides contemplated by the present invention. Thus, the

Suitable solvents include but are not limited to methylene

amount of protein or polypeptide useful in the drug delivery

chloride, hexa?uoroacetone, hexa?uoroisopropanol,

system of the present invention is an amount sufficient to

acetonitrile, hexane, cyclohexane and the like.

achieve the desired therapeutic effect. For guidance, refer

The preferred solvents are methylene chloride, hexa?uo

ence may be made to any standard reference text such as 5 roacetone and hexa?uoroisopropanol.

A precipitate is thus obtained by forcing the polymer and

Goodman and Gilman, The Pharmacological Basis of

Therapeutics.

protein/polypeptide out of the solution. The precipitation
may be achieved by any technique knoWn in the art. Suitable
techniques include adding a solvent in Which the polymer is

In order to improve the properties and appearance of the
drug delivery system of the present invention, one or more

excipients, coloring agents, isotonic agents, antioxidants,

10

not soluble or cooling the solution to achieve precipitation.

and the like, may be added to the drug delivery system, for

The preferred precipitation technique involves forcing the

example, excipients such as starch, dextrin, mannitol,
sorbitol, cyclodextrin and tragacanth, coloring agents such

polymer out of solution using a solvent in Which the protein/
polypeptide is soluble but in Which the polymer is not
soluble. Suitable solvents include Water, aqueous buffer,
aqueous-alcoholic mixtures and the like. Under the proper
conditions of stirring, the particle siZe of the precipitate can
be controlled. The precipitate is then ?ltered and dried.

as beta-carotene, red color No. 2 and blue color No. 1,
isotonic agents such as sodium chloride and glucose, and
antioxidants such as ascorbic acid and erythorbic acid and
their salts or esters. Actual methods of preparing such
dosage forms are knoWn or Will be apparent, to those skilled
in the art. For example, see Remington’s Pharmaceutical

Sciences, 17th edition, 1985, ed. Alfonso R. Gennaro, Mack
Publishing Company, Easton, Pa. 18042.
The nature of the excipient(s) Will preferably aid in the
manufacture of the dosage form selected. Certain dosage

15

The precipitate includes both protein/-polypeptide and
20

protein/polypeptide in vivo is thereby achieved.
If the microsphere technique is used as depicted in FIG.
2, spherical polymer matrices or microspheres having a
diameter range betWeen about 1 to 150 microns

forms provide a more extended release of the biologically

The microspheres may be prepared by forming emulsi?ed
droplets or spheres consisting of a homogeneous mixture of
polymer (or copolymer) and solvent from a solution of a

teriZed as an af?nity or as some type of association or

preselected polymer dispersed in a continuous (non-solvent

interaction betWeen the polymer and the protein/
35

The physical interaction or adsorption is not clearly
understood but it may be characteriZed someWhat by What it
is not. The interaction does not appear to be chemical in
nature, i.e., it is not a covalent bond, hydrogen bond or the
like. This deduction is on the basis of Differential Scanning

can be

prepared in narroW siZe ranges for targeting to various organ
or organ systems via parenteral injection or inhalation as
shoWn in FIG. 4. A more preferred range for the spherical
polymer matrices of microspheres is betWeen about 0.5 to 70
microns.

active protein or polypeptide. These extended release dosage
forms are particularly useful and offer increased ?exibility in
the administration of the protein or polypeptide.
An important feature of the present invention is the fact
that there is a physical interaction betWeen the hydrophobic
biodegradable polymer and the protein or polypeptide of the
present invention. That physical interaction may be charac

polypeptide.

polymer and a physical interaction is present betWeen the
protein/polypeptide and polymer. Controlled release of the

phase). Removal of the solvent from the sphere by any one
or combination of (1) freeZe drying, or (2) solvent extraction
creates the microsphere. The protein or polypeptide may
then be added.

In particular, in the microsphere method, the desired
polymer or copolymer and the protein or polypeptide and
40

other agents(s) are dissolved separately in a suitable solvent.
The polymer and polypeptide solution are mixed together to

Calorimetry, Infrared Spectroscopy, Fourier Transform
Infrared Spectroscopy, Raman Spectroscopy and Fourier

provide a polymer concentration generally ranging betWeen

Transform Raman Spectroscopy. While not Wishing to be
bound by any theory, the present inventor believes that the
-interaction is hydrophobic in nature and involves the amino
acid chain linkages. Brie?y, it may be depicted as an

about 2.5 to 18% W/W and a polypeptide/polymer ratio
ranging betWeen about 1:1 to 1:100. The temperature of the
resultant solution is generally controlled betWeen about 30°
to 45° C. The polypeptide-polymer solution comprising the

45

equilibrium mechanism:

dispersed phase is dispersed into the continuous phase
containing a surface active agent at a thermostatically con

Calcitonin+PolymerSCalcitonin-Polymer

trolled temperature generally in the range of 10° to 20° C.
Any surface active agent knoWn in the art Would be suitable
in the practice of the present invention so long as it does not
interfere With the activity or interaction betWeen the polymer
and protein/polypeptide. The foregoing may be accom

Such a mechanism Would alloW for incorporation of the
protein or polypeptide into the polymer matrix as Well as
alloWing its release from the matrix When localiZed in a body

compartment in Which the released protein or polypeptide
diffuses from the site.

The drug delivery system of the present invention may be
prepared by any procedure Which alloWs for the formation of
a physical interaction betWeen the hydrophobic biodegrad
able polymer and the protein or polypeptide. TWo such

55

ori?ce noZZle. The continuous phase Which is 5 to 20 times

by Weight of the dispersed phase is then agitated by a
dispersator. FolloWing the introduction of the dispersed

processes may be referred to as the polymer precipitation

technique or the microsphere technique.
In the polymer precipitation technique, the polypeptide
and polymer are mixed together With a suitable solvent to
form a homogeneous liquid state as depicted in FIG. 1.
Any organic or inorganic solvent may be used as long as
both the polypeptide and polymer are soluble in the solvent
and the solvent does not degrade or adversely affect the

polymer or the polypeptide.

plished by any method knoWn in the art, in particular, by
forcing the dispersed phase under pressure through a ?ne

phase, one of tWo recovery methods is utiliZed to stabiliZe
60

and recover the drug-loaded microspheres for ?nal process
ing.

More speci?cally, consistent With the freeZe-dry method,
65

folloWing dispersion, the temperature is maintained at 10° to
20° C., preferably 15° C., for tWo minutes then increased to
45° to 55° C., preferably 50° C., over a three minute period.
Vigorous agitation of the mixture is continued during this
period. When the temperature reaches 50° C., either a

US 6,306,406 B1
10
refrigerant solution is circulated through the jacket from the
bath or the container is immersed in dry ice-methanol and
cooled to a temperature Which Will freeZe the drug-polymer

solvent phase and not the continuous phase. The suspension
or emulsion (solid dispersion phase in liquid continuous
phase) is quickly transferred to precooled vials (—40° to
—60° C.) and cooled to —40° to —60° C. in a freeZe dryer,
freeZer or dry ice-acetone bath. The solvent in the suspended

droplets (microspheres) and the continuous phase solvent
are removed by freeZe drying. Upon completion of the
freeZe dry cycle the microspheres are Washed With a suitable
solvent, ?ltered and air dried.
In the solvent extraction method of the invention, folloW
ing dispersion, the temperature is maintained at 10° to 20°
C., preferably 15° C., for tWo minutes, then increased to 45°
to 55° C., preferably 50° C., over a three minute period. The
dispersion is then transferred to a vessel containing a diluent

10
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solvent at room temperature or the diluent solvent is added

to the dispersion. Agitation may be continued for approxi

mately 30 minutes using an appropriate mixing technique.
During the process the dispersed phase solvent is removed
from the polypeptide-polymer-solvent emulsion droplets by

20

parenteral (e.g., intravenous, intraarterial, intramuscular,
subcutaneous or intraocular) or inhalation routes of admin
istration but can be used for oral and intranasal administra
tion if such administration enhances bioavailability or

extraction causing solidi?cation of the droplets. The solid
spheres are then removed by ?ltration, Washed With a
suitable solvent and air dried.

microspheres of the present invention. Identi?able param
eters include the concentration of polymer in the dispersed
phase, the temperature of the dispersed phase at the time of
dispersion, the concentration of surfactants in the dispersed
phase as Well as the ratio of incorporated agent to polymer
in the dispersed phase. It Will be appreciated that the
concentrations, temperatures and ratios referred to herein
above and in the Examples set forth operable ranges and that
other numerical expressions may apply as different solvents,
polymers, proteins, polypeptides and the like, are selected.
The present inventor Wishes to emphasiZe that the inter
action betWeen the protein/polypeptide and the polymer of
the present invention is unique. In the prior art, there Was no
af?nity betWeen the active drug substance and the polymer.
In fact, in some instances, the af?nity of the drug Was much
greater for the solvent in Which the polymer and drug Were
dissolved. Thus, in the prior art systems, When the polymer
Was precipitated from the solution, the drug remained pre
dominantly in the solution.
The drug delivery systems in accordance With the present
invention are ideally suited for administration by the

reduces side effects. In particular, the macroparticulate sys
25

tems in the proper siZe range, i.e., about 0.5 pm to about 5

Solvents for the dispersed phase and the continuous phase

pm, can also be administered orally for adsorption and/or

Will of course differ in order to attain phase separation and
are, therefore, selected based upon the solvent requirements
for each phase. More particularly, the solvent for the dis

pinocytosis by the mucosal cells lining the gastrointestinal

persed phase should preferably dissolve the polymer and the
incorporated agent and remain in the emulsi?ed droplets
With the drug and polymer in the continuous phase until

30

leached out by a diluent solvent or removed by vaporization
or evaporation. In this Way pores are optionally formed in
the drug-polymer matrix. In the case of polyglycolic acid
into Which Water soluble markers or agents are incorporated,

35

hexa?uoroacetone sesquihydrate is an appropriate solvent.
Other solvents Which can be used, depending upon the

ably selected With respect to the intended route of admin

istration and conventional pharmaceutical practices. For
example, for parenteral injection, dosage unit forms may be
utiliZed to accomplish intravenous, intramuscular or subcu

taneous administration, and for such parenteral

characteristics of the polymer and incorporated agents,

include Water, hexa?uoro-isopropanol, methylene chloride,

tract. Such administration permits transfer of the incorpo
rated agent intact to the systemic, lymphatic and secretory
systems of the body.
It Will be appreciated by those skilled in the art that the
drug delivery system of the present invention may be
administered alone or in admixture With appropriate phar
maceutical diluents, carriers, excipients or adjuvants suit

administration, suitable sterile aqueous or non-aqueous solu
40

acetonitrile, tetrahydrofuran, hexane and benZene. Solvents
for the continuous phase should not dissolve the polymer

tions or suspensions, optionally containing appropriate sol
utes to effectuate isotonicity, Will be employed. LikeWise for

inhalation dosage unit forms, for administration through the

and should emulsify the dispersed phase. Suitable solvents

mucous membranes of the nose and throat or bronchio

include, but are not limited to, benZene, dioxane, acetone,

pulmonary tissues, suitable aerosol or spray inhalation com

methylene chloride, chloroform, carbon tetrachloride,

45

toluene, ethyl alcohol, acetonitrile, p-xylene,

positions and devices Will be utiliZed.
Consistent With other preferred embodiments of the

tetrahydrofuran, mineral oil, glycerin and mixtures of these

present invention, the drug delivery system of the invention

solvents.

may be additionally coated or modi?ed to advantageously

in?uence the targeting of the release of the incorporated drug

A diluent (non-solvent) phase can also be employed to

dilute the continuous phase folloWing dispersion of the
polymer polypeptide solution. The diluent should be mis
cible With the continuous phase and dispersed phase solvents

50

bodies or receptor site speci?c drugs Which may be the same
or different from those incorporated in the microsphere

but not dissolve the polymer or incorporated agent.

Examples of suitable solvents include 1,4-dioxane,

cyclohexanone, acetone, ethanol, isopropanol, acetonitrile,
dimethylformamide, tetrahydrofuran, cyclohexanol and the

therein to preselected target cells, tissues or organs. For

example, the drug delivery microspheres may be coated With
various agents, e.g., polymers, proteins, surfactants, anti

55

Whereby the release of the incorporated drug is concentrated
at the targeted system. Additionally, the coatings can be pH
sensitive so as to effect protection folloWing oral adminis

like.

tration and transit through the stomach.

The concentration of polymer in the dispersed phase

In order further to illustrate the present invention and the

directly in?uences the porosity or “void” space in the ?nal
microsphere product as Well as the shape of the microsphere.
A concentration of 2.5% to 10% W/W polymer yields dimen

advantages thereof, the folloWing speci?c examples are
60

sionally suitable spherical particles. With respect to the

EXAMPLE 1

concentration of the protein or polypeptide, up to 50% by
Weight of the polymer has been achieved With consistent
results.

It has been determined that certain processing parameters
in?uence the recovery methods as Well as the resultant

given, it being understood that same are intended only as
illustrative, not limitative.

Molecular Interaction of Salmon Calcitonin With
65

Polyglycolic Acid
The present example Was intended to quantify chemical
and/or physical association betWeen salmon calcitonin and

US 6,306,406 B1
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polyglycolic acid (PGA) having a molecular Weight of
40,000 Daltons.

that used for PGA, except that methylene chloride Was
substituted for HFA and the calcitonin Was suspended rather
than dissolved in the methylene chloride. In addition, since
methylene chloride and buffer are not miscible, salmon
calcitonin Was extracted from methylene chloride in buffer.
The aqueous phase Was separated, centrifuged and the
supernatant Was analyZed spectrophotometrically for salmon

Approximately ?ve mg of calcitonin Were quantitatively
Weighed and placed in each of a series of 5 ml volumetric
?asks. Hexa?uoroacetone sesquihydrate (HFA) Was added

dropWise until the calcitonin dissolved completely. A 5%
PGA in HFA solution Was quantitatively added dropWise to
each ?ask to provide a mass of PGA covering the range of
0 to 26.3 mg. The ?asks Were agitated for 5 minutes to mix
the solution. Each ?ask Was then ?lled to the 5 ml mark With

phosphate buffer (pH 7.3). The addition of buffer precipi
tated the PGA plus any calcitonin that had bound With the
polymer. The resulting mixture Was centrifuged and the
supernatant Was analyZed spectrophotometrically for salmon
calcitonin content. 26 mg of PGA (40,000 MW) removed
approximately 4.1 mg (83%) of salmon calcitonin. The

calcitonin. The results are set forth in Table III.

15

results are set forth in Table I.

TABLE I
PGA
MASS

SUPER
NATANT
ABS

CALCITONIN
CONC.

CALCITONIN
REMOVED

%
CALCITONIN

(mg)

(275 nm)

(mg/ml)

(mg)

REMOVED

0.00
5.73
7.81
7.89
11.8
13.2
14.0
15.8
18.4
10.4
21.0
22.3
23.7
26.3

0.390
0.342
0.285
0.356
0.213
0.257
0.220
0.176
0.086
0.165
0.068
0.161
0.105
0.066

TABLE III

10

PGA
MASS

SUPER
NATANT
ABS

CALCITONIN
CONC.

CALCITONIN
REMOVED

%
CALCITONIN

(mg)

(275 nm)

(mg/ml)

(mg)

REMOVED

0.00
2.68
4.81
10.28
14.95
20.40

0.401
0.226
0.186
0.147
0.105
0.159

1.05
0.592
0.488
0.386
0.276
0.417

0.055
2.04
2.36
2.77
3.62
3.02

1.03
40.8
47.2
55.4
72.4
60.3

20

1.020
0.895
0.746
0.932
0.558
0.673
0.576
0.461
0.226
0.432
0.175
0.422
0.276
0.174

0.099
0.125
1.07
0.340
1.71
1.64
2.02
2.69
3.87
2.54
4.10
2.95
3.62
4.13

1.90
2.71
22.3
6.80
38.0
32.7
41.2
53.7
77.4
54.0
82.1
58.6
72.4
82.6

EXAMPLE 4

Molecular Interaction of Salmon Calcitonin With

Pure Polymer
Approximately 100 mg of PGA (MW 40,000) Was placed
in a vial. Ten ml of a 1 mg/ml calcitonin in phosphate buffer

30

(pH 7.3) Were added to the vial. The polymer Was suspended
in the calcitonin solution by placing the vial in an ultrasonic
bath for 10 minutes. The suspension Was then centrifuged
and the supernatant Was analyZed spectrophotometrically.

This procedure Was repeated for PGA (MW 100,000), PGL
and PLA (dl-type) polymers, With the revision that all
quantitative amounts Were halved for the PGL and PLA
trials. The results are set forth in Table IV.
35

TABLE IV
EXAMPLE 2
MASS

SUPER
NATANT
ABS

POLYMER

(mg)

(275 nm)

(mg)

REMOVED

PGA

99.1

0.4022

0.723

0.723/991

99.3

0.3501

1.143

1.143/993

Molecular Interaction of Salmon Calcitonin With

Poly(Glycolic-Co-Lactic Acid)
The procedure of preparing the poly(glycolic-Co-lactic
acid) (PGL) having a molecular Weight of 50,000 micro

40

spheres Was similar to that used for PGA, except the
hexa?uoro-2-propanol Was substituted for HFA. Above 8

CALCITONIN mg SCT per
REMOVED mg POLYMER

(40,000)
PGA

(100,000)
mg of PGL over 80% of salmon calcitonin Was removed.
45 PGL
The results are set forth in Table II.
(50,000)

50.0

0.4144

0.457

0.457/503

50.0

0.2474

2.772

2.772/500

PLA

(dl-type)
(50,000)

TABLE II
PGA
MASS

SUPER
NATANT
ABS

CALCITONIN
CONC.

CALCITONIN
REMOVED

%
CALCITONIN

(mg)

(275 nm)

(mg/ml)

(mg)

REMOVED

0.00
2.64
4.13
5.52
6.51
8.45
11.53
13.57
20.97

0.360
0.306
0.210
0.191
0.147
0.065
0.047
0.027
0.034

0.941
0.801
0.550
0.501
0.386
0.172
0.125
0.0725
0.0908

0.591
0.995
2.15
2.69
2.87
3.64
4.37
4.44
4.95

11.1
19.9
43.9
51.8
59.8
80.8
87.5
92.5
91.6

50

precipitation process. PLA (dl-type) shoWed the highest
a?inity to bind With salmon calcitonin When suspended in a

1 mg/ml solution.
55

some efforts Were made to determine the nature of the

association betWeen drug and polymer. UtiliZing differential

EXAMPLE 3

Molecular Interaction of Salmon Calcitonin With

dl-type having a molecular Weight of 50,000, Was similar to

Since the PGA system Was the polymer of choice for

preparing microspheres by the freeZe drying technique,

60

Polylactic Acid
The procedure for preparing the polylactic acid (PLA),

The pure polymers shoWed a binding a?inity, up to 5.5%,
Which Was less than the molecular interaction during the

65

scanning calorimetry there Was some shifts in the melting
points of salmon calcitonin and PGA When these agents
Were combined in microspheres. Changes Were also
observed in the IR. and Raman spectra. All of these suggest
an association but do not conclusively point to the precise
nature of the interaction. HoWever, Fourier Transfer Raman
spectrometry did not shoW any discernible differences. This
suggests that the interaction is not chemical or covalent in
nature.

US 6,306,406 B1
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EXAMPLE 5

added to the samples and placed in a 37° C. shaker bath.
Samples Were WithdraWn at predetermined time intervals
and analyZed for drug content. As shoWn in FIG. 6, the initial
release Was rapid. A release of 22% occurred at Zero time,
folloWed by another 21% of the total drug released in less
than 2 hours. This Was folloWed With only negligible release
for the next 30 hours of about 0.1% per hour. A signi?cant
amount of salmon calcitonin appears to be still Within the
matrix or bound to the polymer.

Preparation of a Salmon Calcitonin-PGA

Precipitated System
1. Precipitation With Water
49.3 mg of salmon calcitonin Was placed in a vial and
dissolved With 0.35 ml HFA sesquihydrate. A4.5 g of a 10%
PGA-HFA solution containing 450 mg of PGA Was added

dropWise to the solution While stirring With a magnetic
stirring bar. The mixture Was agitated for 5 additional
minutes. A pH 7.3 phosphate buffer Was then added to the

10

mixture to precipitate the polymer. Turbidity suggested the

In Vivo Assessment of Salmon Calcitonin

precipitation of the polymer. The mixture Was agitated tWo
more minutes using a vortex mixer and then centrifuged for
10 minutes at 3000 rpm. The supernatant Was saved for
analysis and the precipitate dried in a loW pressure chamber
for a feW hours. The salmon calcitonin of the content of the

supernatant Was analyZed spectrophotometrically and the
amount of the active agent removed by the polymer Was
calculated. Loading Was betWeen 6.0 to 8.0% by Weight of

polymer.

Sustained Release From Biodegradable

Microspheres
15

20

2. Precipitation With Ethyl Alcohol
The buffer Was replaced by ethanol to precipitate the
polymer to attempt to improve the yield. The total solid input
(polymer+salmon calcitonin) Was 502 mg in this prepara

EXAMPLE 7

Biodegradable microspheres containing salmon calcito
nin Were prepared With polyglycolic acid, 40,000D by a
freeZe-drying technique as depicated in FIG. 2. Salmon
calcitonin microspheres With different salmon calcitonin
contents Were characteriZed for particle siZe, porosity, spe
ci?c surface area and in- vitro release. The sustained hypoc
alcemic effect Was assessed by subcutaneous injection in

male Wistar rats, folloWed by blood sampling via femoral
artery catheter at de?ned time intervals and assaying for
25

tion. A loading of 6.4 to 8.0% Was used.

serum calcium concentrations. Drug loads of 0.3, 4.5 and
7.5% Were evaluated and a level of 0.3% Was found to be

effective in producing a sustained hypocalcemic effect. With
EXAMPLE 6

this drug load, salmon calcitonin microspheres containing

Characterization of Salmon Calcitonin-PGA

40, 120 and 360 mU of salmon calcitonin per 100 g body

Microspheres and Precipitate

30

1. Blank Microspheres

a) Drug Load

hours With free salmon calcitonin. Additionally, salmon

Microspheres Were prepared as described in Example 5

calcitonin blood levels Were sustained at concentrations

using 100,000 molecular Weight polyglycolic acid. Because
of the association tendency of salmon calcitonin With polyg
lycolic acid, it Was not possible to use the precipitation
technique to determine actual drug load. The 30 minute

Weight Were administered as illustrated in FIG. 7. The
hypocalcemic effect Was sustained for a 24 hour period With
the salmon calcitonin microspheres as compared to 2 to 3

35

higher than baseline for a period of ?ve days.
From the foregoing description, one of ordinary skill in
the art can easily ascertain the essential characteristics of the

extraction technique in buffer Was more indicative of actual

instant invention, and Without departing from the spirit and

salmon calcitonin content. By the extraction method and
HPLC analysis, a drug content of 8.21 % W/W Was calculated

scope thereof, can make various changes and/or modi?ca
tions of the invention to adapt it to various usages and
conditions. As such, these changes and/or modi?cations are
properly, equitably and intended to be Within the full range

40

as 82% incorporation efficiency.
b) In Vitro Release of Salmon Calcitonin
TWenty mg of PGA-salmon calcitonin microspheres Were

of equivalence of the folloWing claims.
What is claimed is:

loaded into a test tube. Ten ml of a 0.1M phosphate buffer,

pH 7.4, containing EDTA Were added and the tubes trans

45

ferred to a 37° C. Water bath. Results of this study are shoWn

in FIG. 5. Nineteen pg salmon calcitonin/mg microspheres

1. A drug delivery system for controlled release of
calcitonin, said delivery system comprising a biodegradable
hydrophobic polymer selected from the group consisting of

polyglycolic acid, polylactic acid, copolymers of glycolic

Were released initially as a burst. This initial release Was

acid and L- or D,L-lactic acid, and copolymers of glycolide

folloWed by a fast release of 50% of the total drug in less
than tWo hours. At this point, a sloW release folloWed and 22

and L- or D,L-lactide; and calcitonin, Wherein calcitonin is
adsorbed to the polymer and a hydrophobic bond is present

pg salmon calcitonin/mg microspheres (22% of total drug)
Was released in the folloWing 29 hours. The data from this

betWeen said polymer and calcitonin Whereby protection and

study suggested that salmon calcitonin remains stable in the
phosphate buffer for about 35 hours.

controlled release of calcitonin is achieved in vivo.

2. Precipitate
a) SiZe Distribution

55

2. A process for preparing a drug delivery system for
controlled release of calcitonin, said process comprising:

(a) dissolving calcitonin and a hydrophobic biodegradable
polymer selected from the group consisting of polyg

HIAC/ROYCO counter-siZe analyZer Was used to analyZe
the drug loaded precipitate for siZe distribution. As shoWn in
FIG. 2, D50, the number median diameter, Was approxi
mately 2.8 pm and 99% of the particles Were in the range of

lycolic acid, polylactic acid, copolymers of glycolic
acid and L- or D,L-lactic acid, and copolymers of

2—10 pm. The geometric standard deviation, og=1.83 is

glycolide and L- or D,L-lactide, in a ?rst solvent and
dispersing the solution in a second solvent to form

indicative of a fair monodispersity. MMD, mass median
diameter, Was calculated to be 4.39 pm.

(b) extracting the ?rst solvent from the microdroplets,

b) In Vitro Release of Salmon Calcitonin from Precipitate
TWo 18 mg samples of salmon calcitonin-PGAprecipitate

microdroplets,
such that an interaction occurs at the aqueous polymer
65

interface causing the calcitonin to adsorb to the

Were quantitatively transferred to test tubes. Ten ml of a

polymer, and hardening the polymer such that

0.1M phosphate buffer, pH 7.4, containing EDTA Were

calcitonin-loaded microspheres are formed.

US 6,306,406 B1
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3. A process for preparing a drug delivery system for
controlled release of calcitonin, said process comprising:

infrared spectroscopy, Raman spectroscopy and Fourier

transform Raman spectroscopy, Whereby protection and
controlled release of calcitonin is achieved in vivo.

(a) dissolving calcitonin and a hydrophobic biodegradable
polymer selected from the group consisting of polyg

lycolic acid, polylactic acid, copolymers of glycolic

13. A process for preparing a drug delivery system for
controlled release of calcitonin, said process comprising:

acid and L- or D,L-lactic acid, and copolymers of
glycolide and L- or D,L-lactide, in a ?rst solvent, and

(a) dissolving calcitonin and a hydrophobic biodegradable
polymer selected from the group consisting of polyg

(b) adding a second solvent in Which calcitonin is soluble,

lycolic acid, polylactic acid, copolymers of glycolic

causing the polymer to precipitate and form micropar
ticles to Which calcitonin is adsorbed.
4. The process as claimed in claim 2, Wherein the micro
spheres are reduced in siZe.
5. The process as claimed in claim 3, Wherein the micro
particles are reduced in siZe.
6. A process as claimed in claim 3 Wherein said second

10

microdroplets,
(b) extracting the ?rst solvent from the microdroplets,
15

a) dissolving calcitonin and a hydrophobic biodegradable
polymer selected from the group consisting of polyg

(a) dissolving calcitonin and a hydrophobic biodegradable
polymer selected from the group consisting of polyg

lycolic acid, polylactic acid, copolymers of glycolic
acid and L- or D,L-lactic acid, and copolymers of

lycolic acid, polylactic acid, copolymers of glycolic
25

b) dispersing said ?rst phase in a continuous second

acid and L- or D,L-lactic acid, and copolymers of
glycolide and L- or D,L-lactide, in a ?rst solvent, and

(b) adding a second solvent in Which calcitonin is soluble,

solvent phase to obtain a suspension, and

causing the polymer to precipitate and form micropar

c) removing said ?rst and second solvents from said

ticles to Which calcitonin is adsorbed, Wherein a hydro

suspension by freeZe-drying to obtain microspheres
containing the calcitonin and polymer.

phobic bond is present betWeen said polymer and
calcitonin.

8. The process as claimed in claim 7, Wherein the micro
spheres are reduced in siZe.

15. A process for preparing a drug delivery system for
controlled release of calcitonin, said process comprising:

9. A drug delivery system for controlled release of calci
tonin prepared according to the process of claim 2.
10. A drug delivery system for controlled release of
calcitonin prepared according to the process of claim 3.
11. A drug delivery system for controlled release of
calcitonin prepared according to the process of claim 7.
12. A drug delivery system for controlled release of

a) dissolving calcitonin and a hydrophobic biodegradable
polymer selected from the group consisting of polyg

lycolic acid, polylactic acid, copolymers of glycolic
acid and L- or D,L-lactic acid, and copolymers of
glycolide and L- or D,L-lactide, in a ?rst solvent to
form a ?rst phase;

b) dispersing said ?rst phase in a continuous second

calcitonin, said delivery system comprising a biodegradable

solvent phase to obtain a suspension, and

hydrophobic polymer selected from the group consistion of

polyglycolie acid, polylactic acid, copolymers of glycolic

c) removing said ?rst and second solvents from said

suspension by freeZe-drying to obtain microspheres

acid and L- or D,L-lactic acid, and copolymers of glycolide
and L- or D,L-lactide; and calcitonin, Wherein calcitonin is
adsorbed to the polymer and a hydrophobic bond is present
betWeen said polymer and calcitonin, and not a covalent

such that an interaction occurs at the aqueous polymer

interface causing the calcitonin to adsorb to the poly
mer and form a hydrophobic bond, and hardening the
polymer such that calcitonin-loaded microspheres are
formed.
14. A process for preparing a drug delivery system for
controlled release of calcitonin, said process comprising:

solvent is selected from the group consisting of Water,
aqueous buffer and aqueous-alcoholic mixture.
7. A process for preparing a drug delivery system for
controlled release of calcitonin, said process comprising:

glycolide and L- or D,L-lactide, in a ?rst solvent to
form a ?rst phase;

acid and L- or D,L-lactic acid, and copolymers of
glycolide and L- or D,L-lactide, in a ?rst solvent and
dispersing the solution in a second solvent to form
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containing the calcitonin and polymer, Wherein calci
tonin is adsorbed to the polymer and a hydrophobic
bond is present betWeen said polymer and calcitonin.

bond or hydrogen bond as determined by differential scan

ning calorimetry, infrared spectroscopy, Fourier transform
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